Presentation Controversies and Advances 2023 Renal Denervation Will Be an Option for Most Hypertensive Patients! Presenter: Michael J. Bloch November 30, 2023
News Daily News Symplicity Spyral Approved: FDA Clears Second Renal Denervation System Todd Neale November 20, 2023
News Daily News Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle Todd Neale September 12, 2023
News Daily News As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions L.A. McKeown August 18, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Daily News PA Catheters in Cardiogenic Shock: Patchy Usage, Potential Gains Shelley Wood June 22, 2023
News Daily News US Athlete’s Death Highlights Risk of Hypertensive Disorders of Pregnancy Michael O'Riordan June 19, 2023
News Daily News New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF L.A. McKeown April 19, 2023
News Daily News To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC Yael L. Maxwell April 12, 2023
News Daily News Inactivity Pandemic Poised to Undo CVD Prevention Advances Michael O'Riordan April 11, 2023
News Daily News Brain Areas Identified Linking High BP and Cognitive Impairment Todd Neale March 31, 2023
News Conference News AHA 2022 Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering Caitlin E. Cox November 08, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Daily News Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes Todd Neale September 14, 2022